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In this issue of the journal, David Linch and colleagues pre-
sent a comprehensive analysis on the NPM1 mutant allele
frequency in a large cohort (n = 876) of younger acute mye-
loid leukaemia (AML) patients (Linch et al., 2019). The sig-
nificance of the NPM1 mutant allelic burden for prediction
of clinical outcome in AML had previously been addressed
in smaller cohorts of patients, leading to conflicting conclu-
sions. While Patel et al (2018) proposed that a high NPM1
mutant variant allele frequency (VAF) at diagnosis predicts
an unfavourable outcome of treatment, which they more
recently extended by demonstrating that this correlates with
minimal residual disease status in first remission (Patel et al.,
2019), other comparable studies showed that NPM1 mutant
VAFs correlated with leukaemia burden but not with survival
(Abbas et al., 2019). In line with this latter publication, the
data presented by Linch et al (2019) also show that different
levels of the NPM1 mutational burden do not have predictive
value for complete remission (CR) and overall survival rates
in a multivariate analysis. This also applied to patients
receiving an allograft in first CR, a subset of patients in
which high NPM1 VAF had a particularly adverse impact in
the studies reported by Patel et al (2018, 2019).
What lessons can we learn from these apparent controver-
sies? First of all, it is relevant to ask what the reported differ-
ences in VAF really meant. Because DNA was isolated from
bone marrow or blood buffy coat cells and percentages of
AML blasts in the test samples were not reported, variable
admixture of non-leukaemic cells probably affected the VAFs
and prohibited accurate estimations of leukaemic burdens.
Hence, it cannot be reliably concluded whether the VAF
cut-offs to discriminate subgroups reflected levels of
(sub-)clonality, normal cell admixture or a combination of
these. Conceivably, discrepancies between the studies may be
partly explained by differences in sample purities. Irrespective
of the underlying explanation, the recommendation of Linch
et al (2019), that the binary presence or absence of an NPM1
mutation rather than variations in VAFs is the most robust
and should therefore preferably be used in therapeutic man-
agement makes sense, also because inter-laboratory variations
in sample preparations will make VAF cut-offs ambiguous.
A more general question of interest is how clonal burdens
will impact on the efficacy of new therapeutic agents target-
ing substrates with specific mutations. Currently, such trials
are underway with inhibitors of mutant isocitrate dehydroge-
nase 1 and 2 (IDH1 and IDH2) and in AML cases with
mutations or internal tandem duplications (ITDs) in FLT3,
encoding FMS-like tyrosine kinase 3 (FLT3). Without going
into details of patient selection criteria and setup of these tri-
als, it is obvious that clonal burdens of the mutations within
the AML blast population at initiation of treatment pre-
dictably have an impact on responses to these inhibitors. In
cases with clonal heterozygous or homozygous mutations
(VAFs ~ 50% or more), the choice for using targeting drugs
is obvious. In contrast, in cases with subclonal mutations in
IDH1/2 or FLT3, criteria for making this choice are less clear.
If VAFs reveal that mutant subclones are minor, let’s say
below 20%, it is unlikely that the drugs will exert a measur-
able therapeutic effect.
But what about patients in which major mutant subclones
are present? Here, several lines of reasoning can be followed.
One may predict that targeting these clones will only have a
short-term clinical impact by reducing tumour load, but will
not erase the founder AML clone and thus fail to contribute
to durable responses. On the other hand, it can be argued
that reducing these subclones might be of longer-term thera-
peutic benefit, for instance because these subclones could
trigger bone marrow niche components to promote growth
and survival of the entire AML blast population. From a
more negative perspective, it is equally possible that targeting
major subclones may give more niche space for IDH1/2 or
FLT3-ITD mutant-negative resistant founder clones and thus
have an adverse effect on durable remissions.
Whether the current and future trials will provide mean-
ingful answers to discriminate between these possibilities will
depend on how patients will be stratified based on VAFs,
essentially along the lines presented by Linch et al (2019).
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However, here it will be essential to use pure (>90%) AML
blasts for the analysis to avoid normal cell admixture as a
major confounder. While these trials are underway, parallel
studies in patient-derived xenograft models might give addi-
tional clues as to whether targeting AML with various levels
of subclonality will have clinical benefit.
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